Prosecution Insights
Last updated: November 04, 2026
Application No. 19/107,535

VEPDEGESTRANT FOR USE IN TREATING CANCER

Non-Final OA §103§DOUBLEPATENT
Filed
Feb 27, 2025
Priority
Aug 31, 2022 — provisional 63/402,671 +3 more
Examiner
CHANDRAKUMAR, NIZAL S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arvinas Operation Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
7m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
1301 granted / 1792 resolved
+12.6% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
84 currently pending
Career history
1894
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
36.8%
-3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1792 resolved cases

Office Action

§103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Qian US11597720 and Gutierrez, Arch Pathol Lab Med. 2011 January ; 135(1): 55–62. Qian the instantly pictured active ingredient is a degrader of estrogen receptor. At column 1036 Qian teaches PNG media_image1.png 416 496 media_image1.png Greyscale Qian teaches at column 392 lines 55+; at column 395 that “preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day’. Further it is noted that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. The differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). The above Qian teaching corresponds to instant claims 1-4 in anticipatory manner. Qian also teaches the limitations of dependent claims (claim 5 column 392; claim 7-10 column 398; claim 11, 15 column 398 line 34-45; claim 12 ER + column 3 lines 3-6 and column 398 lines claim 14-20 column 8 line 28) As to claims 12 and 13: It is well-known that HR+/HER2− Breast Cancer is the most common subtype of breast cancer, accounting for roughly 70% to 80% of all cases. For example,. Gutierrez titled ‘Biology, Detection, and Clinical Implications’ teaches that Human epidermal growth factor receptor-2 (HER2/neu, c-erbB2), one of a family of four membrane tyrosine kinases, was found to be amplified in a human breast cancer cell line twenty five years ago (1), and this amplification was shown to be important in the pathogenesis and progression of human breast cancer two years later (2). Since that time, HER2 amplification and resultant HER2 protein overexpression have been linked to important tumor cell proliferation and survival pathways; several drugs have been developed to target the pathway; and, the detection of HER2 has become a routine prognostic and predictive factor in breast cancer (see page 1). Further Gutierrez, teaches that HER2 testing results by IHC fall into three categories, positive, equivocal and negative (Table 3, and Fig. 2). Each of these results triggers different patient management (see bottom of page 3). Obviousness can be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. Accordingly, the claims do not recite an unobvious distinction over the prior art. Further, a reference is relevant not only for what it expressly teaches, but also for what it would have conveyed to one of ordinary skill in the art. See In re Opprecht, 12 USPQ2d 1235, 1236 (Fed. Cir. 1989); In re Bode, 193 USPQ 12 (CCPA 1976). In light of the foregoing discussion, the Examiner finds that the claimed subject matter as a whole would have been obvious to one of ordinary skill in the art at the time the invention was made, in view of the cited references and the knowledge generally available in the art. Accordingly, the claims are rejected under 35 U.S.C. § 103. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Choo, “In vitro Drug-Drug Interaction Assessment of GDC-0810, a Novel and Potent Selective Estrogen Receptor Degrader” (Abstract #233) 28th EORTC-NCI-AACR Symposium, (2016). Groheux, “Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors” Cancer 119(11):1960-68 ( 2013). US 10034860 Estrogen Receptor Modulator For The Treatment Of Locally Advanced Or Metastatic Estrogen Receptor Positive Breast Cancer. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 12-14 of U.S. Patent No. US11597720. Although the claims at issue are not identical, they are not patentably distinct from each other because the conflicting claims contain overlapping subject matter. Claim 14 of US11597720, differs from the instant claim in the specific dosage for treating (breast) caner. That the effective amount noted in US11597720 claim 14 encompasses the instant dose. For the definition of what the ‘effective amount’ of this claim 14, disclosure in the specification is consulted. The instant dose is explicitly noted at column 395 lines 22-37 of US11597720. Note that reliance on specification of a potentially conflicting patent or application is generally prohibited. However limited exceptions do exist. Exceptions to the General Prohibition of Using the Disclosure of a Potentially Conflicting Patent or Application include Dictionary for claim terminology, Portions of the disclosure which provide support for the claims in the potentially conflicting patent or application. The MPEP refers to two exceptions to the general prohibition of using the disclosure of a potentially conflicting patent or application in an ODP-Obviousness analysis. The two exceptions are: 1. The disclosure can be used as a dictionary for claim terminology; and 2. “[T]hose portions of the specification which provide support for the patent claims may also be examined and considered when addressing the issue of whether a claim in the application defines an obvious variation of an invention claimed in the patent” (MPEP § 804). The MPEP further notes: The court in Vogel recognized “that it is most difficult, if not meaningless, to try to say what is or is not an obvious variation of a claim,” but that one can judge whether or not the invention claimed in an application is an obvious variation of an embodiment disclosed in the patent which provides support for the patent claim. According to the court, one must first “determine how much of the patent disclosure pertains to the invention claimed in the patent” because only “[t]his portion of the specification supports the patent claims and may be considered.” The court pointed out that “this use of the disclosure is not in contravention of the cases forbidding its use as prior art, nor is it applying the patent as a reference under 35 U.S.C. 103 since only the disclosure of the invention claimed in the patent may be examined.”) The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs June 2022 41:6, 801-804. Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324–330. Claims 1-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-31 of U.S. Patent No. US12208095 further in view of US11597720 and Gutierrez, Arch Pathol Lab Med. 2011 January ; 135(1): 55–62. Although the claims at issue are not identical, they are not patentably distinct from each other because the conflicting claims contain overlapping subject matter. The entirety of discussion under 35 USC § 103 is incorporated here in the obviousness analysis. The difference is that claimed method of 12208095 includes addition previously well-known anticancer agent. This rejection is based on the well-established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients, In re Sussman, 136 F.2d 715, 718, 58 USPQ 262, 264 (CCPA 1943). Also "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose ...[T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (citations omitted). The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs June 2022 41:6, 801-804. Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324–330. Claims 1-17 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim s 1-5,14,16,36-40,77,79-82,93,102-109 and 138-139 of copending Application No. 17548842 (reference application) further in view of US11597720 and Gutierrez, Arch Pathol Lab Med. 2011 January ; 135(1): 55–62. Although the claims at issue are not identical, they are not patentably distinct from each other because the conflicting claims contain overlapping subject matter. The entirety of discussion under 35 USC § 103 is incorporated here in the obviousness analysis. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Feldman, Understanding ‘Evergreening’ : Making Minor Modifications Of Existing Medications To Extend Protections, Health Affairs June 2022 41:6, 801-804. Dwivedi, Evergreening: A deceptive device in patent rights, Technology in Society 32 (2010) 324–330. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Feb 27, 2025
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774276
MALT1 Modulators and Uses Thereof
2y 1m to grant Granted Oct 27, 2026
Patent 12767668
IMIDAZOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
3y 5m to grant Granted Oct 20, 2026
Patent 12767644
USE OF 3-ARYLPHTHALIDES AND DERIVATIVES THEREOF AS ANTI-INFLAMMATORY AGENTS
2y 8m to grant Granted Oct 20, 2026
Patent 12758562
SYNTHESIS AND PROCESSING OF POLY(PRO-DRUG) MATERIALS FOR EXTENDED DRUG RELEASE AND USES THEREOF
4y 11m to grant Granted Oct 13, 2026
Patent 12753175
PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE
4y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
91%
With Interview (+18.3%)
2y 3m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1792 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month